Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Chris Chlebowski

Chris Chlebowski

NESH Alumni Practitioner Directory

Title: Treatment of SARS-CoV2 MRNA injection injuries using isopathic preparations of Aspergillus Niger

Biography

Biography: Chris Chlebowski

Abstract

Introduction: The rollout of the experimental MRNA injections for the treatment of SARS-CoV2 have resulted in a high number of injured patients. Injury types include, but are not limited to, neurological, mast cell activation, reactivation of quiescent infections, gastrointestinal distress, and autoimmune activation and reactivation.  As conventional medicine has very little to offer these patients remedies from the natural world must be found to treat and cure these patients.  Our clinical observations suggest that the use of commercially available preparations of diluted and potentized Aspergillus Niger resulted in improvement in a large percentage of patients.

Methods: All patients with SARS-CoV2 MRNA experimental injection injuries seen at the Phosphorus Center during a one-year period were enrolled in cohort study. Each patient underwent a comprehensive intake and examination, and when indicated, patients were given a preparation of diluted Aspergills Niger to self-administer at home between regular follow-up visits.

Results: All patients experienced improvement in their primary symptoms as well as marked improvement in ADL’s.

Conclusion: There is a significant decrease in symptoms and improvement in ADL’s in SARS-CoV2 injection injured patients treated with the use of a dilution of Aspergillus Niger. Further studies should be conducted to determine why this compound has utility in the context of injuries from the experimental SARS-CoV2 MRNA injections.